Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$6.1B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the biotechnology sector, focusing on developing innovative therapies for patients with significant unmet medical needs. With a market cap of $5 billion, the company is positioned to impact the healthcare landscape through its specialized drug development efforts.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.18

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal strong demand for Kiniksa's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, beating expectations by 50%. The stock reacted positively, gaining 23.48% the next day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to maintaining strong financial performance.
Plans for potential product launches in the near future.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Kiniksa's upcoming earnings, especially given the strong performance last quarter.

Bull Case

If Kiniksa can replicate or exceed its previous EPS surprise, it could lead to significant stock appreciation and renewed investor confidence.

Bear Case

Conversely, any miss on EPS or lack of revenue guidance could lead to a sharp decline in stock price, as seen in previous quarters.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.18

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal strong demand for Kiniksa's products.

Market Reaction

N/A

The stock's historical reaction to earnings surprises can provide insight into investor sentiment and potential volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, a strong EPS could reinforce investor confidence and drive the stock price higher.

What guidance will management provide for future revenue growth?

Clear guidance on revenue expectations can help investors gauge the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to maintain strong EPS growth due to its innovative pipeline and recent successful trials.

Supporting Evidence

Kiniksa's recent EPS surprise of 50% indicates strong operational performance.

The company's focus on unmet medical needs could drive demand for its products, contrary to cautious market sentiment.

The options market's pricing suggests expectations of significant movement, indicating investor uncertainty.

Key Risk

If Kiniksa's EPS exceeds $0.25, it could challenge the current cautious consensus and prompt a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be critical in determining whether Kiniksa can sustain its growth trajectory and meet investor expectations.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.15 would confirm the bear case, suggesting potential issues with product demand or market conditions.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, history indicates a likely decline of about 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for key therapies.
2Management's outlook on revenue growth for the next quarter.
3Details on potential product launches and market entry strategies.
4Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.18

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal strong demand for Kiniksa's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, beating expectations by 50%. The stock reacted positively, gaining 23.48% the next day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to maintaining strong financial performance.
Plans for potential product launches in the near future.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Kiniksa's upcoming earnings, especially given the strong performance last quarter.

Bull Case

If Kiniksa can replicate or exceed its previous EPS surprise, it could lead to significant stock appreciation and renewed investor confidence.

Bear Case

Conversely, any miss on EPS or lack of revenue guidance could lead to a sharp decline in stock price, as seen in previous quarters.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.18

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal strong demand for Kiniksa's products.

Market Reaction

N/A

The stock's historical reaction to earnings surprises can provide insight into investor sentiment and potential volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, a strong EPS could reinforce investor confidence and drive the stock price higher.

What guidance will management provide for future revenue growth?

Clear guidance on revenue expectations can help investors gauge the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to maintain strong EPS growth due to its innovative pipeline and recent successful trials.

Supporting Evidence

Kiniksa's recent EPS surprise of 50% indicates strong operational performance.

The company's focus on unmet medical needs could drive demand for its products, contrary to cautious market sentiment.

The options market's pricing suggests expectations of significant movement, indicating investor uncertainty.

Key Risk

If Kiniksa's EPS exceeds $0.25, it could challenge the current cautious consensus and prompt a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be critical in determining whether Kiniksa can sustain its growth trajectory and meet investor expectations.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.15 would confirm the bear case, suggesting potential issues with product demand or market conditions.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, history indicates a likely decline of about 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for key therapies.
2Management's outlook on revenue growth for the next quarter.
3Details on potential product launches and market entry strategies.
4Insights into competitive positioning within the biotechnology sector.